ELI-012

N/A

Report date: 2024/12/02 13:50:00

Base Information

Drug NameELI-012

Drug Alias NameELI012

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionAlbumins modulatorsHuman leukocyte antigen modulators

TargetsAlbuminsHuman leukocyte antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesElicio Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesElicio Therapeutics

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A